title: Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study.
abstract: To evaluate the effect of adding neoadjuvant chemotherapy to surgery and radiation therapy for locally advanced resectable oral cavity squamous cell carcinoma, 24 patients with T3 or T4a oral cavity squamous cell carcinoma were randomly assigned to surgery alone or Docetaxel, Cisplatin, and 5-FU (TPF) induction chemotherapy followed by surgery. All patients were planned to receive chemoradiotherapy after surgery. The primary end-points were organ preservation and progression-free-survival. SPSS version 17 was used for data analysis. Median follow-up was 16 months. The median age of the patients was 62 years old (23-75 years). Man/woman ratio was 1.13. The primary site of the tumor was the tongue in most patients (48%). No significant difference was observed between pathologic characteristics of the two groups. Chemotherapy group showed 16% complete pathologic response to TPF. No significant difference in organ preservation surgery or overall survival was detected. However, the patients in the chemotherapy group had longer progression-free-survival (P=0.014). Surgery followed by chemoradiotherapy with or without TPF induction results in similar survival time. However, progression-free-survival improves with the TPF induction chemotherapy. Studies with more patents and new strategies are recommended to evaluate organ preservation improvement and long-term outcomes.
authors.affiliation: Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. ssadighi@tums.ac.ir.
authors.forename: Sanambar
authors.initials: S
authors.lastname: Sadighi
authors.affiliation: Department of Head and Neck Surgical Oncology and Reconstructive Surgery, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. keihani@chafa.ir.
authors.forename: Amanolah
authors.initials: A
authors.lastname: Keyhani
authors.affiliation: Department of Head and Neck Surgical Oncology and Reconstructive Surgery, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. harirchi@sina.tums.ac.ir.
authors.forename: Iraj
authors.initials: I
authors.lastname: Harirchi
authors.affiliation: Department of Head and Neck Surgical Oncology and Reconstructive Surgery, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. agharacheii@yahoo.com.
authors.forename: Ata
authors.initials: A
authors.lastname: Garajei
authors.affiliation: Radiotherapy Oncology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. maghili@sina.ac.ir.
authors.forename: Mahdi
authors.initials: M
authors.lastname: Aghili
authors.affiliation: Radiotherapy Oncology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. akazemian@sina.ir.
authors.forename: Ali
authors.initials: A
authors.lastname: Kazemian
authors.affiliation: Department of Ear, Nose and Trout, Valiasr Hospital, Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran. ssadighi@tums.ac.ir.
authors.forename: Maziar
authors.initials: M
authors.lastname: Motiee Langroudi
authors.affiliation: Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. kzendeh@yahoo.com.
authors.forename: Kazem
authors.initials: K
authors.lastname: Zendehdel
authors.affiliation: Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. nariman@yahoo.com.
authors.forename: Nariman
authors.initials: N
authors.lastname: Nikparto
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000473:pathology / Q000628:therapy*; D020360:Neoadjuvant Therapy / Q000379:methods; D010865:Pilot Projects; D043823:Taxoids / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil